Original from: Genomeweb
Image Credit: DiaSorin Official
DiaSorin Molecular announced on Monday that its Simplexa COVID-19 & Flu A/B Direct test has received CE marking.
The multiplex test is designed for use on the Liaison MDX instrument and differentiates between SARS-CoV-2 and influenza A/B nucleic acids from one sample in one reaction well.
It was validated with more than 80 strains of influenza, as well as emerging SARS-CoV-2 variants, said Cypress, California-based DiaSorin Molecular, which is part of Saluggia, Italy-based DiaSorin Group.
The test is run directly from nasopharyngeal swabs without needing off-board extraction and will be submitted to the US Food and Drug Administration for 510(k) review, the firm said.
DiaSorin received Emergency Use Authorization from the FDA in March 2020 for its Simplexa COVID-19 Direct test and FDA clearance for its Simplexa Flu A/B and RSV Direct Gen II kit in September 2020, which can be used with the COVID-19 test.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.